Ken Griffin Nrx Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.66 - $1.4 $8,123 - $17,232
-12,309 Reduced 98.03%
247 $0
Q4 2022

Feb 14, 2023
BUY
$0.79 - $9.19 $9,919 - $115,389
12,556 New
12,556 $13,000

Others Institutions Holding NRXP

# of Institutions
2
Shares Held
17.4K
Call Options Held
0
Put Options Held
0
View Full List

About NRX Pharmaceuticals, Inc.

NRXP Quotes by TradingView
  • Ticker NRXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,641,296
  • Market Cap $111M
  • Description
  • NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...
More about NRXP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email